ARTIFICIAL INTELLIGENCE IN NANOPARTICLE-BASED DRUG DELIVERY:RECENT ADVANCES AND FUTURE PERSPECTIVES.

Nanoparticle-based drug delivery is an emerging strategy in drug research due to its ability to protect the drug from degradation, control the release of a drug and deliver the drug to specific tissues. Creating appropriate formulations of nanoparticles, however, is time consuming because many factors play a role in the physical properties and the performance of nanoparticles in the body. Artificial intelligence (AI), such as machine learning (ML) and deep learning (DL), could aid with this process by sifting through experimental data and uncovering patterns that might be beneficial. The review focuses on recent advances in the design, selection of materials, formulation development and optimization using AI in the design of nanoparticles. It also explains the basics of drug loading, encapsulation efficiency, drug-release profile, particle size, polydispersity index (PDI), and zeta potential that can be estimated using AI-based models.They are also beginning to be discussed in the context of targeted delivery, such as identification of targets, surface engineering and prediction of interactions between nanoparticles and biology. In addition, examples of application in cancer therapy, RNA loaded lipid nanoparticles, drug delivery to the cardiovascular system and arthritis therapy and personalized nanomedicine are emphasized. Recent progress in the field of nanoinformatics, big data analysis, quality by design (QbD) approaches with the aid of artificial intelligence, and multiscale modelling further opens the potential for more systematic development of nanocarriers. While achieving these breakthroughs, data quality, a lack of datasets, model interpretability, experimental validation, and standardization and regulatory requirements are still significant hurdles to clinical translation. In summary, the combination of AI and the use of nanoparticles could play a role in enhancing the drug delivery development process by providing more efficient, predictive, and personalized strategies, provided that computational predictions are complemented with experimental validation and reliable data.[1]

Authors

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-14
DOI
https://doi.org/10.5281/zenodo.24214953
Primary Topic
Nanoparticle-Based Drug Delivery
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

ARTIFICIAL INTELLIGENCE IN NANOPARTICLE-BASED DRUG DELIVERY:RECENT ADVANCES AND FUTURE PERSPECTIVES.

Yogita Lanke, Samiksha Jadhav, Sujata Nagare, Payal Khairmode
Zenodo (CERN European Organization for Nuclear Research)
Nanoparticle-Based Drug Delivery
article

ARTIFICIAL INTELLIGENCE IN NANOPARTICLE-BASED DRUG DELIVERY:RECENT ADVANCES AND FUTURE PERSPECTIVES.

Yogita Lanke, Samiksha Jadhav, Sujata Nagare, Payal Khairmode
article en

Abstract

Nanoparticle-based drug delivery is an emerging strategy in drug research due to its ability to protect the drug from degradation, control the release of a drug and deliver the drug to specific tissues. Creating appropriate formulations of nanoparticles, however, is time consuming because many factors play a role in the physical properties and the performance of nanoparticles in the body. Artificial intelligence (AI), such as machine learning (ML) and deep learning (DL), could aid with this process by sifting through experimental data and uncovering patterns that might be beneficial. The review focuses on recent advances in the design, selection of materials, formulation development and optimization using AI in the design of nanoparticles. It also explains the basics of drug loading, encapsulation efficiency, drug-release profile, particle size, polydispersity index (PDI), and zeta potential that can be estimated using AI-based models.They are also beginning to be discussed in the context of targeted delivery, such as identification of targets, surface engineering and prediction of interactions between nanoparticles and biology. In addition, examples of application in cancer therapy, RNA loaded lipid nanoparticles, drug delivery to the cardiovascular system and arthritis therapy and personalized nanomedicine are emphasized. Recent progress in the field of nanoinformatics, big data analysis, quality by design (QbD) approaches with the aid of artificial intelligence, and multiscale modelling further opens the potential for more systematic development of nanocarriers. While achieving these breakthroughs, data quality, a lack of datasets, model interpretability, experimental validation, and standardization and regulatory requirements are still significant hurdles to clinical translation. In summary, the combination of AI and the use of nanoparticles could play a role in enhancing the drug delivery development process by providing more efficient, predictive, and personalized strategies, provided that computational predictions are complemented with experimental validation and reliable data.[1]

Zenodo (CERN European Organization for Nuclear Research)
Nanoparticle-Based Drug Delivery
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon